OncLive® On Air cover image

S6 Ep42: Jabbour Highlights New Data With Asciminib and Ponatinib in CML

OncLive® On Air

00:00

ASCEMBL Efficacy Results at 24 Weeks

Elias Jabbour reports higher MMR at 24 weeks with asciminib (25%) versus bosutinib (13.2%), supporting approval.

Play episode from 02:49
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
 Get the app